---
layout: minimal-medicine
title: Lobaplatin
---

# Lobaplatin
### Generic Name
Lobaplatin

### Usage
Lobaplatin is a chemotherapy medication belonging to the platinum-based antineoplastic drug class.  It was investigated in clinical trials (Phase 2) for the treatment of specific cancers, namely breast cancer and hepatocellular carcinoma (liver cancer).  However, its development was discontinued in 2011.  It's crucial to understand that Lobaplatin is **not currently commercially available** for general use. Any information presented here is for educational purposes based on past research and should not be interpreted as a recommendation for treatment.

### Dosage
Because Lobaplatin's development was discontinued, there are no officially approved dosage recommendations for general use.  The specific dosages and administration methods explored in clinical trials varied depending on the type of cancer and other factors related to the patient's health. This information is not available for public distribution and would only be found in detailed clinical trial reports, which are not accessible to the general public.

### Side Effects
Since Lobaplatin's clinical development has ceased, comprehensive data on all possible side effects is not readily available to the general public.  However, based on its mechanism of action and the known side effects of other platinum-based chemotherapy drugs, it's reasonable to expect potential side effects to include:

* **Common:** Nausea, vomiting, diarrhea, fatigue, loss of appetite, hair loss, kidney problems (nephrotoxicity), anemia.
* **Less Common but Serious:**  Severe allergic reactions, nerve damage (peripheral neuropathy), hearing loss (ototoxicity), heart problems, blood clots.


It's important to note that this list may not be exhaustive.  Any individual experiencing side effects from a platinum-based chemotherapy drug should seek immediate medical attention.

### How it Works
Lobaplatin, like other platinum-based chemotherapy drugs, works by damaging the DNA of cancer cells. It does this by forming cross-links between strands of DNA, preventing the cancer cells from replicating and ultimately leading to their death (apoptosis).  The drug's specific effect on the *c-Myc* gene, a gene involved in cell growth and division, was also investigated during clinical trials.  The interference with *c-Myc* expression is thought to be another contributing factor in Lobaplatin's anti-cancer activity.

### Precautions
Due to the discontinuation of Lobaplatin's development, comprehensive precaution information is not publicly available.  However, based on the nature of the drug and similar platinum-based chemotherapies, the following precautions are likely to have applied:

* **Contraindications:**  Lobaplatin would likely be contraindicated in patients with severe kidney or liver disease, as these organs are responsible for processing and eliminating the drug.  Pregnant or breastfeeding women would also have been strongly advised against using this medication.
* **Drug Interactions:**  Lobaplatin could potentially interact with other medications, particularly those affecting kidney or liver function.
* **Vulnerable Groups:**  As with all chemotherapy drugs, children and older adults would likely require careful monitoring and adjusted dosages.  Pregnant and breastfeeding women would likely have been advised against using this drug due to potential harmful effects on the fetus or infant.


### FAQs
Due to the discontinued development of Lobaplatin, most FAQs would be directed towards researching scientists or oncologists involved in clinical trials. Information regarding its use, storage, and safety would not be accessible to the general public in the same way that it would be for commercially available medications.  Any questions about this drug should be directed to a medical professional specializing in oncology and/or clinical trials.
